Vectura Confirms Sandoz as Partner on VR315 and VR632
News Sep 09, 2008
Combination therapy for asthma and COPD is the biggest and fastest growing sector of the respiratory market, with annual sales currently exceeding US$9 billion. VR315 is being jointly developed as a generic product delivered with Vectura’s GyroHaler® dry powder inhaler (DPI) delivery device. Vectura licensed the European rights for VR315 to Sandoz in March 2006 and the US rights
were licensed to them in December 2006. In December 2007, Sandoz exercised an option to license VR632 in Europe. VR632 is also being developed as a generic combination product using the GyroHaler® DPI.
Vectura is due to receive up to 38 million Euro in milestones and development funding prior to the launch of VR315 and VR632 in Europe, and will earn royalties on all product sales as well as a margin on the commercial manufacture and supply of GyroHaler®. Vectura is also due to receive a share of profits from all Sandoz VR315 US sales, as well as up to $63 million upon achievement of pre-determined development and commercial milestones. Costs for the US development of VR315 are being shared between Vectura and Sandoz on a defined basis.
At a Sandoz investor day on 3 September, a video of the manufacturing facilities for these products, which are now operational, was shown and can be found as part of the web cast of the event at www.novartis.com. Sandoz has invested over $50 million in these manufacturing facilities.
Postpartum hemorrhaging is the world's leading cause of death for women during and after childbirth, and the third-leading cause in the United States alone. The drug 'misoprostol' although affordable, has dangerous side effects, including uterine cramping, heart attack, toxicity in the brain and spinal cord, fetal death and fetal heart abnormalities. Development of a safer drug may be on the horizon, based on new researchREAD MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019